<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-OV45FP1B</identifier><date>2022</date><creator>Bratkovič, Tomaž</creator><relation>documents/doc/O/URN_NBN_SI_doc-OV45FP1B_001.pdf</relation><relation>documents/doc/O/URN_NBN_SI_doc-OV45FP1B_001.txt</relation><format format_type="issue">2</format><format format_type="volume">73</format><format format_type="type">article</format><format format_type="extent">str. 107-114</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">108481539</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-OV45FP1B</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">CGRP</subject><subject language_type_id="slv">Klinične raziskave</subject><subject language_type_id="slv">Migrena</subject><subject language_type_id="slv">monoklonsko protitelo</subject><subject language_type_id="slv">Nevropatije</subject><subject language_type_id="slv">učinkovitost</subject><subject language_type_id="slv">varnost</subject><title>Monoclonal antibodies for the prevention of migraine</title><title>Monoklonska protitelesa za preprečevanje migrene</title></Record>